The FDA has approved only four mAb treatments for melanoma to date: namely, ipilumimab, which targets CTLA4; nivolumab and pembrolizumab, which target PD-1; and opdualag, a combination therapy including nivolumab and relatlimab-rmbw which targets lymphocyte activation gene-3. Here, CTLA4 is linked to melanoma.